Developing a DiGA: Is It Worth the Investment?
The German DiGA market grew 61% in 2025 to reach €171M — yet only 7% of companies that consult BfArM ever list a product. Our new business case model shows exactly what commercial performance a DiGA developer needs to justify the investment, and why market position is everything.
A market growing fast, but with a steep entry filter
The German prescription app (DiGA) market has attracted enormous developer interest since the Fast-Track pathway opened in 2020. Research2Guidance estimates that approximately 800 companies held consultations with BfArM between 2020 and January 2026. Of those, only 246 — roughly 31% — went on to submit a formal application. Just 74 received a positive decision, and 58 DiGAs are currently listed.
The message is clear: the pathway is real, but the attrition is severe. Regulatory complexity, clinical evidence requirements, and the cost of building a compliant digital medical device eliminate the majority of early-stage ambitions before a product ever reaches a physician’s prescription pad.
A €13M investment to reach the starting line
Our standard cost model for a standalone DiGA developer launched in 2025–2026 totals approximately €13 million over the first five commercial years (2027–2031). That breaks down into:
- €2.67M pre-launch investment: product strategy, software development, clinical study, regulatory and MDR compliance, cybersecurity, BfArM submission, and commercial launch preparation.
- €2.07M annual operating costs: software maintenance, cloud infrastructure, customer support, quality management, post-market surveillance, physician marketing, and general administration — the largest single line being sales and physician outreach at €900k per year.
These are not vanity numbers. They represent the baseline a credible, compliant, commercially-ready DiGA requires. The question every developer and investor must then answer is: what prescription volume do we realistically need to recover them?
Performance tier is the single most important variable
Using 2025 market data — 694,928 total activated prescriptions across 58 DiGAs — Research2Guidance modelled three distinct performance tiers for a new DiGA launched in 2027.
The spread is striking. A top-tier DiGA generates more than ten times the five-year revenue of a middle-tier product — at exactly the same pricing. Adoption, not reimbursement rate, is the dominant driver of value creation.
The revenue ramp: winners take almost all
Under R2G’s revenue model (€550 in year 1, €227 from year 2 onward — reflecting the standard German price-step mechanism), a top-tier DiGA launched in 2027 generates €13.9M in its first commercial year, growing to €66.7M by 2031. By contrast, a middle-tier product generates €1.2M in year one and reaches only €5.6M by 2031.
The implication is not subtle. A middle-tier DiGA barely covers its annual operating costs from year two onward. It recovers the full €13M investment only marginally over the five-year horizon. A low-tier DiGA — with fewer than 500 activated prescriptions per month — generates €1.8M in cumulative revenue against €13M in costs. It is not commercially viable as a standalone product.
What it takes to break even
The business case model makes the break-even threshold explicit.
To reach middle-tier performance by 2031, a DiGA needs to achieve more than 2,000 activated prescriptions per month. That requires a sustained physician outreach and patient engagement programme — not a launch event.
A Top 10 tier DiGA, by contrast, produces a five-year operating result of €171M and represents a highly attractive return on the €13M investment. The business case for the market leaders is excellent. The business case for everyone else requires a hard look at the numbers before committing.
Why platform companies have a structural advantage
The analysis points strongly toward one strategic conclusion: the economics of a standalone DiGA are challenging at all but the highest performance tiers. Platform-based DiGA developers — those who can distribute the cost of technology, regulatory infrastructure, quality management, clinical operations, and physician networks across multiple products — face a materially different cost equation.
A standalone developer builds and bears all those costs for a single revenue stream. A platform company amortises them across DiGA A, DiGA B, and DiGA C. The result is a lower average cost per DiGA, a shorter path to break-even, and a more defensible long-term business model. As the market matures and prescription volumes concentrate further in the top tier, this structural advantage will only increase.
Summary
The German DiGA market is real, growing, and commercially attractive — but only for a minority of developers. The data points to three conclusions:
- Market entry is harder than it looks. Only 7% of companies that consult BfArM reach a listed product.
- Break-even requires middle-tier performance at minimum. That means more than 2,000 activated prescriptions per month and a five-year revenue of at least €15.5M against a €13M cost base.
- Platform business models have a structural cost advantage that standalone developers cannot easily replicate.
For investors and pharma/medtech companies evaluating the DiGA channel, the question is not whether the market exists — it is whether you have the commercial infrastructure to compete at the tier where the economics work.
Source: R2G DiGA Business Case Model, June 2026. All revenue figures are illustrative and based on R2G modelling assumptions.
Want to discuss your DiGA business case with our experts? Reach out to the Research2Guidance team at [email protected] , we help pharmaceutical companies, medtech developers, and investors evaluate DiGA market opportunities with independent data and strategic advisory.
